Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO

1 min read

The FINANCIAL — Roche on May 11 announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 29th May – 2nd June in Chicago, United States. These data demonstrate the strength of Roche’s oncology pipeline, particularly in cancer immunotherapy and personalised medicine.

“We’re particularly excited about our data in different types of advanced lung cancer, including pivotal data for alectinib and results of the first randomised study of our investigational immunotherapy, MPDL3280A,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head, Global Product Development. “These results build upon our long-standing commitment to improve outcomes for people with lung cancer, and we hope these data will help us bring new options to treat this devastating disease.”

Updated results from studies of cobimetinib in combination with Zelboraf will be presented during ASCO. Cobimetinib is currently under review with both the US Food and Drug Administration (FDA) and the European Medicines Agency. Data presented at ASCO for alectinib and Gazyva/Gazyvaro will support submissions for marketing authorisation and for MPDL3280A, Roche is discussing interim data from POPLAR, the large, randomised Phase II study with the FDA as part of its Breakthrough Therapy Designation in lung cancer. Preliminary data will also be presented on investigational medicine venetoclax in non-Hodgkin’s lymphoma and multiple myeloma. The FDA recently granted Breakthrough Therapy Designation to venetoclax for people with relapsed/refractory chronic lymphocytic leukemia who have a genetic abnormality known as 17p deletion, according to Merck.


Leave a Reply